Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph I/Ib FT-2102 as Single Agent & in Combo w/ Azacitidine in Pts w/ AML or MDS w/ an IDH1 Mutation

Protocol: OSU-17291

Full Title

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Leukemia Acute Myeloid Leukemia